Bank of New York Mellon Corp - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 98 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2018. The put-call ratio across all filers is 0.96 and the average weighting 1.0%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q4 2018$17,000
-56.4%
85,830
-0.3%
0.00%
Q3 2018$39,000
-9.3%
86,130
+0.3%
0.00%
Q2 2018$43,000
-97.2%
85,830
-87.0%
0.00%
Q1 2018$1,539,000
-21.5%
660,261
-4.4%
0.00%
-100.0%
Q4 2017$1,961,000
+10.2%
690,631
+11.0%
0.00%
Q3 2017$1,780,000
+19.9%
622,430
+3.6%
0.00%
Q2 2017$1,484,000
-23.6%
600,525
+11.6%
0.00%
-100.0%
Q1 2017$1,943,000
+3.0%
538,156
+1.1%
0.00%0.0%
Q4 2016$1,886,000
+8.8%
532,540
+24.1%
0.00%0.0%
Q3 2016$1,733,000
-12.4%
428,964
-4.8%
0.00%0.0%
Q2 2016$1,978,000
+12.0%
450,733
-3.5%
0.00%0.0%
Q1 2016$1,766,000
-75.9%
467,229
-0.2%
0.00%
-50.0%
Q4 2015$7,338,000
+50.0%
467,986
+0.8%
0.00%
+100.0%
Q3 2015$4,892,000
-87.8%
464,228
-70.7%
0.00%
-90.9%
Q2 2015$40,008,000
-5.2%
1,586,378
+4.7%
0.01%0.0%
Q1 2015$42,221,000
-7.5%
1,514,926
-39.5%
0.01%
-8.3%
Q4 2014$45,664,000
+53.1%
2,502,063
+8.7%
0.01%
+50.0%
Q3 2014$29,823,000
-59.9%
2,301,161
-49.5%
0.01%
-20.0%
Q2 2014$74,396,000
+815.4%
4,558,584
+891.1%
0.01%
+400.0%
Q1 2014$8,127,000
-33.9%
459,940
-9.5%
0.00%
-33.3%
Q4 2013$12,298,000
-63.8%
508,015
-47.0%
0.00%
-40.0%
Q3 2013$33,968,000
+406.8%
958,734
+123.3%
0.01%
+150.0%
Q2 2013$6,702,000429,2950.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2018
NameSharesValueWeighting ↓
Ridgeback Capital Investments L.P. 1,025,000$24,815,00031.36%
TSP Capital Management Group, LLC 836,342$20,248,0008.80%
Iguana Healthcare Management, LLC 200,000$4,842,0002.76%
First Light Asset Management, LLC 116,096$2,811,0002.38%
SECTORAL ASSET MANAGEMENT INC 2,227,688$53,932,0002.33%
BENNETT LAWRENCE MANAGEMENT L L C/NY 550,735$13,334,0002.05%
Eventide Asset Management 257,000$6,222,0001.92%
Redmile Group, LLC 397,951$9,634,0001.19%
ARDSLEY ADVISORY PARTNERS LP 357,000$8,643,0001.15%
Rhenman & Partners Asset Management AB 90,000$2,179,0000.85%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders